Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study

Journal of Hepatology

Volumn 32, Issue 6, 2000, Pages 1003-1010

  Causse, Xavier ^a,af   Payen, Jean Louis ^b   Izopet, Jacques ^b   Babany, Gérard ^ae   Girardin, Marie France Saint Marc ^ae   Bailly, F ^c   Housset, C ^d   Tran, A ^e   Pariente, A ^f   Lagasse, J ^a   Desmorat, H ^b   Bettan, L ^g   Bloch, F ^h   Couzigou, P ⁱ   Chossegros, P ^c   Laurent, Puig P ^j   Bacq, Y ^k   Douvin, C ^l   Raabe, J ^m   Van Lemmens, C ⁿ   Zarski, J ^o   Bernard, P ⁱ   Rozenbaum, W ^p   Trois Vallets, D ^q   Fischer, D ^r   Sogni, P ^s   Boucher, E ^t   Boyer, N ^u   Lang, J ^v   Danne, O ^w   Barbare, J ^x   Force, G ^y   Schmit, J ^z   Mesnard, B ^aa   Gauthier, A ^ab   Poveda, J D ^ac   Sayada, C ^ad   Olivares, R ^ae   Montestruc, F ^ae   more..

^a Oreléans Regional Hospital   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c University Hospital of Lyon   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

^f Pau Hospital   (France)

^g Villeneuve Saint Georges Hospital   (France)

^h HÔPITAL BROUSSAIS   (France)

ⁱ Brodeaux Pessac University Hospital   (France)

^j BICÊTRE HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l Creteil Hospital   (France)

^m Metz Regional Hospital   (France)

ⁿ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^o GRENOBLE UNIVERSITY HOSPITAL   (France)

^p HÔPITAL ROTHSCHILD   (France)

^q Gonesse General Hospital   (France)

^r Evry General Hospital   (France)

^s Cochin University Hospital ^*  (France)

^t Rennes University Hospital   (France)

^u BEAUJON HOSPITAL   (France)

^v UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^w Pontoise General Hospital   (France)

^x Compiègne General Hospital ^*  (France)

^y Levallois   (France)

^z AMIENS UNIVERSITY HOSPITAL   (France)

^aa CENTRE HOSPITALIER DE TOURCOING   (France)

^ab Marseille University Hospital   (France)

^ac CBMS   (France)

^ad ACTGène Evry   (France)

^ae Roche   (France)

^af CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

more..

Author keywords

Chronic hepatitis C; Hepatitis C virus; HIV infection; Human immunodeficiency virus; Interferon treatment

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONITIS; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME;

EID: 0034044530     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80105-1     Document Type: Article

References (46)

1. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 349:1997;1294.
2. Lot F, Pillonel J, Pinget R, Cazein F, Gouezel P, Laporte A. Diminutionbrutale du nombre de cas de sida. Rôle des nouvelles stratégies thérapeutiques? BEH. 11:1997;43-45.
3. Libbrecht E, Beuscart C, Ajana F, Maniez-Montreuil M, Chidiac C. Infection par le virus de l'hépatite C chez les patients infectés par le virus de l'immunodéficience humaine. Med Mal Infect. 25:1995;117-120.
4. Rey D, Hassairi N, Partisani M, Jacquemin C, Kempf G, de Mautort E, et al. Séroprévalence du virus de l'hépatite C par tests ELISA et RIBA de 2e génération chez des patients infectés par le virus de l'immunodéficience humaine. Med Mal Infect. 25:1995;1125-1131.
5. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol. 31:1993;2679-2682.
6. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatits C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood. 84:1994;1020-1023.
7. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 9:1995;1131-1136.
8. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis. 174:1996;690-695.
9. Sherman KE, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology. 23:1996;688-694.
10. Soriano V, Nedjar S, Garcia-Samaniego J, Bravo R, Castro A, Gonzales J, et al. High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. J Hepatol. 22:1995;598-599.
11. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. Histopathologic findings in chronic hepatitis C. J Hepatol. 24:(Suppl. 2):1996;35-42.
12. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology. 97:1989;1559-1561.
13. Eyster ME, Diamondstone LS, Lien JM, Ehmann C, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr. 6:1993;602-610.
14. Soto B, Sanchez-Quijano A, Rodrigo L, Angel del Olmo J, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 26:1997;1-5.
15. Quan CM, Kradjen M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 17:1993;117-119.
16. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol. 27:1997;18-24.
17. Davis GL, Balart LA, Schiff FR, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
18. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Muray L, Waggoner J, et al. Recombinant interferon-alfa therapy for chronic hepatitis C: a randomized double-blind pacebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
19. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon-alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
20. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human alfa-interferon in patients with chronic non-A, non-B hepatitis: a multicenter controlled trial from France. Hepatology. 13:1991;393-397.
21. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
22. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, et al. Recombinant interferon-alfa for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis. 165:1992;723-726.
23. Marriott E, Navas S, del Romero J, Garcia S, Castillo I, Quiroga JA, et al. Treatment with recombinant alfa-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol. 40:1993;107-111.
24. Mauss S, Heintges T, Adams O, Albrecht H, Niederau C, Jablonowski H. Treatment of chronic hepatitis C with interferonalfa in patients infected with the human immunodeficiency virus. Hepato-gastroenterology. 42:1995;528-534.
25. Leclerc N, Redeker S, Tribout B, Roussel C, Duverlie G, Eb F, et al. Influence de l'infection VIH sur la réponse au traitement par l'interferon de l'hépatite chroníque C. Med Mal Infect. 26:1996;682-686.
26. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J. Interferon alfa for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis. 23:1996;585-591.
27. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology. 1:1981;431-435.
28. Centers for Diseases Control. 1993 revised classification system for HIV infection and expanded surveíllance case definition for AIDS among adolescents and adults. Morb Mortal Weekly Rep. 41:1992;1-19.
29. Halfon P, Ouzan D, Khiri H, Feryn JM. Serotyping and genotyping of hepatitis C virus (HCV) strains in chronic HCV infection. J Med Virol. 52:1997;391-395.
30. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 17:1916;863-871.
31. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 87:1994;555-561.
32. Pol S, Lamorthe B, Trinh Thi N, Thiers V, Carnot F, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 28:1998;945-950.
33. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol. 29:1998;12-19.
34. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
35. Yamada G, Takatami M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 22:1995;1351-1354.
36. Hopf U, Berg T, König V, Küther S, Henft HG, Lobeck H. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and pronostic relevance of HCV genotypes. J Hepatol. 24:(suppl 2):1996;67-73.
37. Davis GL, Lindsay K, Albrecht J. Predictors of response to recombinant interferon treatment in patients with chronic hepatitis C. Hepatology. 12:1990;905.
38. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci. 42:1997;178-185.
39. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol. 21:1994;12-17.
40. BHIVA Guidelines Coordinating Committee. British HIV association guidelines for antiviral treatment of HIV seropositive individuals. Lancet. 349:1997;1086-1092.
41. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS society-USA panel. JAMA. 277:1997;1962-1968.
42. Stratégies d'utilisation des antirétroviraux dans l'infection par le VIH. Rapport d'experts 1998 sous la direction de J Dormont. 1998;Flammarion Médecine-Sciences, Paris.
43. Degos F, Damat V, Chevret S, Gagne S, Bastie A, Riachi G, et al. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. J Hepatol. 29:1998;224-232.
44. Lam N, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 26:1997;226-231.
45. Manesis E, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology. 26:1997;734-739.
46. Reichard O, Norkrans G, Fryden A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-bind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis. Lancet. 351:1998;83-87.